Drugs in Dev. Infections and Infectious Diseases
Phase II/ Phase III
Sweden 
Lead Product(s) : Anakinra
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SOBI's Anakinra Found to Decrease Covid-19 Symptoms in a Small Study
Details : First study to report use of anakinra to treat COVID-19 infection found that high-dose anakinra was safe and was associated with a 90% survival rate and reduced respiratory symptoms associated with severe COVID-19 infection.
Product Name : Kineret
Product Type : Protein
Upfront Cash : Inapplicable
August 05, 2020
Lead Product(s) : Anakinra
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anakinra
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Swedish Orphan Biovitrum AB will begin a short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome in COVID-19 disease.
Product Name : Kineret
Product Type : Protein
Upfront Cash : Inapplicable
March 18, 2020
Lead Product(s) : Anakinra
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
